To address this, we performed a retrospective analysis of a large cohort of patients with relapsed or refractory FLT3-mutated AML treated with single-agent gilteritinib in 38 centers across the UK National Health Service (NHS). The gene discussed is FLT3; the disease is acute myeloid leukemia.